1. Aebi S, Gelber S, Castiglione-Gertsch M et al. (2000) Is chemotherapy alone adequate for young women with est-rogenreceptor positive breast cancer? Lancet 355:1869–1874
2. Albain K, Green S, Ravdin P et al. (2001) Overall survival after Cyclophosphamide, Adriamycin, 5-FU, and Tamoxifen (CAFT) is superior to T alone in postmenopausal, receptor (+), node (+) breast cancer: New findings from phase III Southwest Oncology Group Intergroup-Trial S8814 (INT-0100). Proc ASCO 20: abstract 94
3. Anelli A, Gadelha AP, Albuquerque A A et al (1999) High response rate of paclitaxel (PTX) and Doxorubicin (DOX) as neoadjuvant chemotherapy (NCT) in locally advanced breast cancer (HIB) is associated with P53 status. Proc ASCO 18: abstract 302
4. Benner SE, Clark GM, McGuire WL et al. (1988) Review: Steroid receptors, cellular kinetics, and lymph node status as prognostic factors in breast cancer. Am J Med Sci 196:59–66
5. Bergh J, Wiklund T, Erikstein B et al (2000) Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Lancet 356:1384–1391